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Objective. The aim of this study was to evaluate the clinical relevance of rheumatoid factor (RF) and antibodies against cyclic
citrullinated peptides (anti-CCP) in patients with Sjo¨gren syndrome (SS) secondary to rheumatoid arthritis (RA).
Methods. The study included 118 individuals, and the subjects were divided into three groups: rheumatoid arthritis (RA;
n ¼ 46), RA with secondary Sjo¨gren syndrome (RA/SS; n ¼ 20) and healthy controls (C; n ¼ 52). Clinical and laboratory
characteristics, including ocular, oral, and serum markers, anti-CCP, and rheumatoid factor (RF), were compared in addition to
biopsy of labial minor salivary glands.
Results. The RA group exhibited unstimulated salivary flow rate, and Schirmer test results were similar to those for C and
higher than those for RA/SS (P < .05). Furthermore, the frequency of xerophthalmia and xerostomia was similar among the
RA and C groups, and much higher in the RA/SS group (P < .05). Anti-CCP positivity and serum levels were similar in both RA
groups, irrespective of SS diagnosis (RA  RA/SS; P > .05). RF presented a similar frequency and serum level between the RA
and RA/SS groups (P > .05).
Conclusions. Secondary SS seems to be a cluster of oral and ocular symptoms among patients with RA. Anti-CCP and RF are
not relevant to evaluate the presence of SS among these patients. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:
628-635)Rheumatoid arthritis (RA) is a chronic inﬂammatory
and autoimmune disease of unknown etiology, char-
acterized by progressive and usually symmetric joint
involvement. It affects 1% to 3% of the adult popula-
tion and clearly predominates in females,1,2 with a peak
incidence between ages 35 and 45 years.1-3 RA pro-
gression leads to a decreased ability to perform daily
activities and impairs the quality of life.4,5 It is esti-
mated that the survival of patients with RA is 20%
lower than that of the general population, and this is
particularly related to disease severity.6 Early diagnosis
and prompt treatment are essential for reducing disease
activity, controlling functional disability as well as
preventing irreversible joint damage.7
In addition to polyarticular involvement, RA may
involve several other organs and tissues. Among the
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628immunopathologic process are rheumatoid nodules,
hematologic manifestations, Felty syndrome, lung and
neurologic involvement, amyloidosis, and rheumatoid
vasculitis, as well as renal, cardiac, muscle, and liver
abnormalities.8 Furthermore, involvement of the
exocrine glands, particularly the salivary and lacrimal
glands, is also well known in patients with RA.9,10
Sjogren syndrome (SS) is a chronic systemic in-
ﬂammatory autoimmune disease characterized by lym-
phocytic inﬁltration of the exocrine glands, primarily
the lacrimal and salivary glands, leading to reduced
glandular functions and subsequent oral and ocular
dryness.11 Two clinical forms are classically described:
primary and secondary. Primary Sjögren syndrome
(pSS) is characterized by an autoimmune glandular
disease with some extraglandular features, and its
secondary form (sSS) is described as a glandular
disease associated with collagenoses, such as RA,
systemic lupus erythematosus (SLE), and scleroderma.
The prevalence of sSS ranges from 9% to 19% inStatement of Clinical Relevance
Secondary Sjögren syndrome (sSS) is a distinctive
condition found in individuals with rheumatoid
arthritis. Diagnosis should rely on clinical and minor
salivary gland features, since serologic markers
of rheumatoid arthritis (i.e., rheumatoid factor and
antiecyclic citrullinated peptides) are not discrimi-
natory for sSS.
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RA.12
The diagnosis of both RA and SS are based on a
combination of symptoms, clinical signs, and labora-
tory ﬁndings, since there are no speciﬁc tests to di-
agnose these diseases. Among the available laboratory
tests, rheumatoid factor (RF) has been used as a marker
of RA for over half a century and is still the most
commonly requested test. However, it has been well
documented that patients in the early stages of RA may
be positive for antibodies against cyclic citrullinated
peptides (anti-CCP) even when the RF is negative.13
The anti-CCP test has higher sensitivity and speci-
ﬁcity compared with RF, which makes it a reliable
marker of severe erosive joint disease.13 The
autoantibodies associated with pSS include anti-SSA
(Anti-Ro), anti-SSB (Anti-La), and RF. Moreover,
anti-CCP is not elevated in classic pSS, which can help
distinguish between the articular manifestations of SS
and RA.14 In this context, the aim of this study was to
assess the clinical and serologic proﬁle of sSS, focusing
on the role of RF and anti-CCP as biomarkers identi-
fying sSS among patients with RA.PATIENTS AND METHODS
This case-control study was conducted with 118 in-
dividuals of both genders, over the age of 18 years, who
were divided into three groups: (1) the RA group
(n ¼ 46), (2) the RA/SS group (n ¼ 20), and (3) the
healthy control group (C) (n ¼ 52). The patients with
RA (RA and RA/SS) were recruited from the Rheu-
matology Unit e Hospital das Clínicas, Universidade
Federal de Pernambuco (HC/UFPE). Healthy in-
dividuals were recruited from the Oral Medicine Unit
(UFPE). The local Ethics Committee Board of Health
Sciences Center (UFPE) approved the study under
Report/Protocol No. 124/09, and patients signed an
informed consent before participation.
Diagnosis of RA was established by a rheumatologist
on the basis of the criteria established by the American
College of Rheumatology.15 The diagnosis of sSS was
established according to classiﬁcation criteria proposed
by the American-European Consensus Group.16 The
control group showed no signs of RA and did not
report any autoimmune or immune-mediated disorders,
which was conﬁrmed by clinical and laboratory evalu-
ations. Patients with a history of radiation therapy to the
head and neck area, seropositivity for human immuno-
deﬁciency virus or hepatitis C virus, or diagnosed with
sarcoidosis, amyloidosis, or graft-versus-host disease
were not included in the present study. Patients who
described previous long-term use of antidepressants,anticholinergics, opioid narcotics, antiepileptics, and
anxiolytic drugs were also excluded from the study.
The researchers had access to the medical records of
all eligible patients who met the inclusion criteria. The
relevant data were transferred to a speciﬁc question-
naire. After clinical evaluation, saliva and blood sam-
ples were collected, and minor salivary gland (MSG)
biopsies were performed.Clinical assessment of salivary flow
Whole unstimulated saliva was collected in a sterilized
plastic tube over a period of 15 minutes from both case
and control patients. Unstimulated salivary ﬂow rate
(USFR) was recorded as milliliters per minute. To
avoid a possible effect of the circadian rhythm on
salivary ﬂow rate, the assessment was performed during
the mornings between 9 AM and 12 noon. Patients were
instructed not to eat, drink, or smoke for at least 90
minutes before collection. Values below 0.1 mL/min
were considered positive for hyposalivation.Schirmer test
The Schirmer test was performed according to the
methodology reported elsewhere.17 Patients were
instructed not to use tear substitutes for a period of at
least 60 minutes before the test. A standardized paper
strip (Teste de Schirmer, Ophthalmos, Brazil) was
placed in the lateral canthus away from the cornea of
each eye and left in place for 5 minutes, with the
subject keeping the eyes closed. Readings were
recorded in millimeters of wetting for 5 minutes. A
reading of less than 5 mm/5 min was considered
positive for an aqueous deﬁciency.Laboratory values: anti-CCP, RF, cross-reactive
protein (CRP) and erythrocyte sedimentation rate
(ESR)
Blood samples were collected from patients, by means
of vacuum tubes without anticoagulant (BDVacutainer,
San Antonio, TX). Each blood sample was allowed to
clot for 30 minutes before the serum was processed.
After centrifugation for 15 minutes at 2500 rpm, the
serum was collected by pipetting and placed in labeled
Eppendorf microtubes and stored at 20C until
quantiﬁcation of CRP, RF, and anti-CCP. For the
analysis, all samples were sent to a medical laboratory.
Anti-CCP serum levels were detected by enzyme-linked
immunosorbent assay, and RF was evaluated by neph-
elometry. CRP was analyzed by hs-CRP method for the
Beckman Coulter IMMAGE. To determine ESR, blood
was collected in a 2-mL tube (Vacuette) containing
sodium citrate and immediately sent for analysis.
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Patients were evaluated by a rheumatologist and an oral
medicine specialist on the same day. DAS28/ESR was
based on the number of tender and swollen joints, ESR
value, and an evaluation of the patient’s overall health.
Number of tender and swollen joints and patient’s
overall was obtained during the rheumatology exami-
nation. DAS included an ESR obtained on the same day
of the examination, and it was categorized as remission
(DAS28 2.6), low disease activity (2.6; DAS28
3.2), moderate disease activity (3.2; DAS28 5.1),
and high disease activity (DAS28 >5.1).18Fig. 1. Unstimulated salivary ﬂow rates of rheumatoid
arthritis (RA), secondary Sjögren syndrome (RA/SS), and
control (C) groups.Minor salivary gland biopsy
Minor salivary gland biopsy was suggested for all pa-
tients and was mandatory for patients with RA in whom
the diagnosis of sSS was not established or discarded
after the evaluation of clinical parameters. All biopsies
were performed in the left lower lip by using a scalpel.
A 1- to 2-cm superﬁcial linear incision was performed 1
cm away from midline, and a minimum of four to seven
mucous salivary gland lobules were retrieved from the
submucosa. The salivary gland lobules were ﬁxed in
10% formalin solution and sent for routine histopath-
ologic processing. Microscopic analysis was performed
by an oral pathologist, according to the American-
European Consensus Group microscopic classiﬁcation
criteria (focus score >1).19Statistical analysis
Statistical analyses were performed with the Pearson chi-
square test or the Fisher exact test andKruskalWallis test,
in addition to the Mann-Whitney and Student’s t test with
equal variances. The hypothesis of equal variances was
veriﬁed with the Levene F test, and use of the Kruskal-
Wallis and Mann-Whitney tests was justiﬁed because of
the high variability expressed by the standard deviation.
Statistical signiﬁcance was set at P < .05. Statistical an-
alyses were carried out by using the SPSS for Windows
software program, version 15.0 (Statistical Package for
the Social Sciences, Inc., Chicago, IL).
RESULTS
Gender and age
The study consisted of 118 patients, 11 (9.32%) men
and 107 (90.68%) women, divided into three groups.
The mean age of patients was 50.4 ( 12.7) years in the
RA group; 57.7 ( 10.9) years in the RA/SS group, and
42.3 ( 16.5) years in the control group (C).Oral evaluation
Nineteen RA patients (41.3%) and 16 RA/SS patients
(80%) reported dry mouth (P ¼ .0065; OR ¼ 5.684;95% conﬁdence interval [CI] ¼ 1.74-19.71). The
mean USFR was 0.38 mL/min in the RA group; 0.07
mL/min in the RA/SS group, and 0.33 mL/min in the
C group, with a signiﬁcantly lower rate in the RA/SS
group (P < .001; Figure 1). In addition, the RA/SS
group presented a higher number of patients with
hyposalivation (USFR <0.1 mL/min) (n ¼ 16;
84.2%) compared with the RA group (n ¼ 8;
17.4%) and the C group (n ¼ 9; 17.3%) (P < .001)
(Table I).
Forty labial biopsies were performed in the RA group
(n ¼ 22) and the RA/SS group (n ¼ 18). Microscopic
analysis showed that 18.2% (n ¼ 4) of the patients in
the RA group, and 38.9% (n ¼ 7) of the patients in the
RA/SS group had glandular inﬁltrate compatible with
SS (P ¼ .173).Ocular evaluation
Eighteen patients (39.1%) with RA reported xeroph-
thalmia, and most of those in the RA/SS group (n ¼ 18;
90%) had this complaint (P < .001). When the
Schirmer test was considered as a classiﬁcation crite-
rion, the RA/SS group presented a higher number of
positive cases (19 patients; 95%) than the RA group (17
patients; 39.5%) and the C group (21 patients; 40.4%)
(P < .001) (see Table I).Laboratory values: anti-CCP, RF, CRP, and ESR
Anti-CCP was positive in 39 of 46 subjects (84.8%) in
the RA group, compared with 18 of 20 (90%) in the
RA/SS group (P ¼ .71) and 1 of 52 (1.9%) in the C
group (P < .001). The sensitivity and speciﬁcity of anti-
CCP in the diagnosis of RA were 86% (57/66) and 98%
(51/52), respectively. A higher mean titer of anti-CCP
was found in the RA group (192.2 IU/mL) than in the
Table I. Evaluation of dry mouth, unstimulated salivary ﬂow rate, hyposalivation (USFR <0.1 mL/min), xeroph-
thalmia, Shirmer test, and minor salivary gland biopsy in patients with rheumatoid arthritis (RA) compared with those
with secondary Sjögren syndrome (RA/SS) and control group (C)
Group
RA/SS N (%) RA N (%) C N (%) P value
Xerostomia
Positive 16/20 (80%) 19/46 (41.3%) 6/52 (11.54%) P ¼ .0065*
OR ¼ 5.684
95%CI ¼ 1.74-19.71
Hyposalivation (USFR<0,1 mL/min)
Positive 16/19 (84.2%) 8/46 (17.4%) 9/52 (17.31%) P < .001*
OR ¼ 24.67
95%CI ¼ 5.78-105.3
Xerophothalmia
Positive 18/20 (90%) 18/46 (39.1%) 9/52 (17.31%) P < .001*
OR ¼ 14
95%CI ¼ 2.89 - 67.75
Schirmer Test
Positive 19/20 (95%) 17/46 (39.5%) 21 (40.38%) P < 0.001*
OR ¼ 29.06
95%CI ¼ 3.55-237.8
Biopsy
Positive 7/18 (38.9%) 4/22 (18.2%) P ¼ .173
OR, odds ratio; 95%CI, 95% conﬁdence interval.
*Chi-square test comparing RA/SS and RA.
Table II. Evaluation of antibodies for cyclic citrullinated peptides (anti-CCP), rheumatoid factor (RF), cross-reactive
protein (CRP), and erythrocyte sedimentation rate (ESR) in patients with rheumatoid arthritis (RA) compared with
those with secondary Sjögren syndrome (RA/SS)
Group
Variable Statistics RA/SS N (%) RA N (%) P value
Anti-CCP
Positive 18/20 (90%) 39/36 (84.8%) P* ¼ .712
Mean (standard deviation) 156.70 (104.51) 192.92 (95.57) Py ¼ .535
Median 205.75 251.69
Range 7.15-254.02 4.98-254.18
RF
Positive 15/20 (75%) 29/46 (63%) P* ¼ .344
Mean (sd) 221.06 (294.24) 128.99 (211.55) Py ¼ .1489
Median 71.30 38.80
Range 20.0-1010.0 20.0-1210.0
CRP
Positive 9/20 (45%) 27/46 (58.7%) P* ¼ .304
Mean (standard deviation) 8.73 (8.29) 10.83 (9.97) Py ¼ .451
Median 4.90 8.30
Range 1.22-34.30 1.16-46.40
ESR
Positive 16/20 (80%) 41/46 (89.1%) P* < .437
Mean 40.30 (26.55) 36.85 (23.89) Py ¼ .670
Median 33.50 31.00
Range 9.0-107.0 9.0-115.0
*Fisher exact test.
yMann-Whitney test.
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IU/mL) (P < .001). However, when the RA and RA/SS
groups were compared, there was no statistically sig-
niﬁcant difference (P ¼ .535) (Table II). The sensitivityand speciﬁcity of RF in the diagnosis of RA were 66%
(44/66) and 100% (52/52), respectively. One patient in
the control group presented with positive anti-CCP with
a low titer (22.11 U/mL; data not shown), but negative
Table III. Evaluation of Disease Activity Score 28
(DAS28), number of tender and swollen joints in
rheumatoid arthritis (RA) compared with secondary
Sjögren syndrome (RA/SS)
Group
Variable RA/SS RA P value
DAS28 Mean (SD)
Median
Range
4.14 (1.54)
4.35
1.61-7.58
4.74 (1.37)
4.78
2.25-7.79
P ¼ .131*
NO tender
joints
3.53 (4.40)
2
0-17
7.58 (8.04)
5
0-28
P ¼ .054*
NO Swollen
Joints
2.42 (4.41)
0
0-16
3.05 (3.30)
2
0-13
P ¼ .077*
*Mann-Whitney test.
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nosis of RA was discarded.
In contrast to anti-CCP, the mean RF was higher in
the RA/SS group (221.06 IU/mL) than in the RA group
(128.99 IU/mL) and the C group (all cases showed less
than 20 IU/mL) (P < .001). However, no statistically
signiﬁcant difference was found when patients from
the RA and RA/SS groups were evaluated separately
(P ¼ .149) (see Table II).
Finally, the mean CRP was signiﬁcant when the three
groups were compared (P < .001), but no signiﬁcance
was observed when the RA and RA/SS groups were
analyzed separately (P ¼ .451). The ESR showed no
signiﬁcant difference between groups, with 80%
(16/20) of positive patients in the RA/SS group and
89% (41/46) in the RA group (P ¼ .437).DAS28 and joint involvement
The assessment of disease activity was performed only
in the RA group (RA/SS and RA groups). The mean
DAS28 was higher in the RA group (4.74) than in the
RA/SS group (4.14) (P ¼ .131). The mean number of
painful and swollen joints was higher in the RA group
than in the RA/SS group (P ¼ .054 and P ¼ .077,
respectively) (Table III).DISCUSSION
In this study, the correlation between RA markers and
disease activity and the diagnosis of sSS was evalu-
ated. In addition, the prevalence of ocular and oral
symptoms of sicca and the prevalence of decreased
lacrimal and salivary ﬂow in Brazilian outpatients with
RA were also evaluated. The main outcome of this
study was that serum levels of RF and anti-CCP were
similar in RA irrespective of SS status, so they were
discriminatory for RA but not for sSS. Patients with
both RA and SS were shown to simultaneouslymanifest most of the oral or ocular signs and symp-
toms. However, patients exclusively with RA had oral
and ocular signs and symptoms similar to those in
healthy controls.
RA is a chronic inﬂammatory musculoskeletal disease
that may cause signiﬁcant morbidity and mortality related
to articular disease as well as extra-articular manifesta-
tions.19 The extra-articular manifestations of RA seem to
represent an indicator of damage or a marker of disease
activity.20 However, the association of intense salivary
gland inﬂammation with extra-glandular manifestations
of SS suggests that glandular immune responses are
related to systemic manifestations of the disease.10
Furthermore, symptoms of sicca are often classiﬁed as
extra-articular manifestations of RA and are related to
disease activity and health status.19 The close association
between RA and SS may depend on the involvement of
periepithelial lymphocytic lesions in both glandular
disease and organ damage.10 Nevertheless, SS presents
a unique feature, namely, the activation of epithelial
cells that assume a vital function in disease
pathogenesis, including the expression of immune-
competent molecules implicated in innate and acquired
immune responses.21 Therefore, this activation in a
favorable immune setting of RA seems to favor SS
development in this subset of patients and also justify
the high prevalence of SS among patients with
connective tissue disease.21 Moreover, there is an
association between salivary gland inﬂammation and
extra-glandular manifestations of SS, suggesting that
glandular immune responses are related to systemic
manifestations of SS.10
The distinction between SS and RA is of great
importance. First, pSS patients may present articular
symptoms, simulating RA. Second, andmore commonly,
SS may follow RA in a RA/SS scenario. Furthermore,
sicca symptoms are classically described as an extra-
articular manifestation of RA,22 and it may make the
diagnosis of SS even more unlikely. Clinicians should
consider that patients with RA/SS present a plethora of
systemic complications (e.g., anemia, leukopenia,
thrombocytopenia, interstitial lung disease, autoimmune
liver disease, and kidney disease23) so that the diagnosis
of sSS is warranted in order to allow prompt
recognition and adequate management of the associated
conditions.
The adequate recognition of SS has implications that
extend beyond clinical issues. Even not so common dis-
eases, such as systemic lupus erythematosus, present
more genetic studies than SS. These studies need a strict
disease deﬁnition; therefore, large cohorts of patients with
clearly deﬁned SS are not commonly found even in
research centers.24 Nevertheless, it is currently
understood that the pathogenesis of SS represents a
multigenic and multifactorial process that manifests
Table IV. Sicca signs and symptom and reported prevalence of Sjögren syndrome (SS) in patients with rheumatoid
arthritis (RA) from 1999 to date
Study
N
Oral
symptom %
Ocular
symptom %
Reduced
USFR %
Reduced
ScT % Reported SS
prevalenceRA C RA C RA C RA C RA C
Uhlig et al., 199922 636 d 50 d 38 d 17 d 27 d 7%
Gilboe et al., 200123 81 81 33.3 19.7 51.9 29.6 16 d 21 d 3/81
3.7%
Brun et al., 200324 70 d 32.1 d 46.4 d NA 33.9 d NA
Helenius et al., 200511 77 (24 RA) 77 NA 30/77
39%
Aliko et al., 201018 88 88 44.3 13.6 40.9 8.0 27.3 9.1 48.9 20.5 13/88
14.8%
Antero et al., 201125 82 d 35.3 57.3 d NA 41.4 d 20/82
24.3%
Haga et al., 201226 307 d 28% NA NA 11/307
3.6%
He et al., 201327 509 187 31.2 85 22.5 72.7 NA NA 74/509
14.54%
Present study 66 52 56.06 11.54 54.54 17.31 36.36 17.31 54.54 40.38 20/66
30.30%
RA, rheumatoid arthritis; SS, Sjögren syndrome; USRF, unstimulated salivar fow rate; ScT, Schirmer I test; NA, not available.
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targets organ dysfunction.11 Evidence suggests that Th1/
Th2 imbalance plays a role in the pathogenesis of SS.25
Th2 cytokines may be predominant in an early phase of
SS, whereas Th1 cytokines seem to be associated with a
later stage of the disease. Interleukin 17A appears to be
implicated in primary SS immunopathology, and
increased levels of this circulating interleukin are
observed in SS.26
Several lines of evidence have indicated a higher
prevalence of oral or ocular signs and symptoms in pa-
tients with RA.22,27 The prevalence of oral and ocular
symptoms in these patients is reported to range from 11%
to 65%, whereas the prevalence of reduced tear and
salivary ﬂow varies from 21 to 70.7 and 12% to 40%,
respectively.22 Table IV compares the frequency of oral
signs and symptoms in patients with RA in several
studies from 1999 to date. They have reported an
elevated frequency of ocular or oral signs and
symptoms but a low frequency of sSS. Moreover,
patients with sSS were not separated from patients with
RA, possibly causing the observation of a higher
frequency of signs and symptoms of sicca.19,20,22,23,27-30
In the present study, we observed that when the patients
with RA were evaluated irrespective of SS status,
xerophthalmia was reported in 54.54% and xerostomia in
53.03% of the sample (data not shown). After separation
of patients with only RA from those with RA/SS, a
prevalence of xerophthalmia was observed in 39.1% of
the RA group and in 90% of the RA/SS group, and
xerostomia in 41.3% and 80%, respectively. Moreover,
hyposalivation and decreased Schirmer I test were more
frequent in the RA/SS group. It could be noted that sSS isa cluster of ocular or oral signs and symptoms among
patients with RA, so patients exclusivelywith RA seem to
present these features in a manner similar to that seen in
healthy controls.
sSS diagnosis requires a systematic evaluation of
several features, including ocular or oral symptoms,
ocular signs, histopathology, and salivary gland
involvement,16 and when this is not systematically
performed, an underreported frequency of sSS is
observed.19,23,28 MSG biopsy seems to be the key
point in this equation, and many clinical studies have
failed to perform this procedure.19,20,22,23,27-30 The lack
of biopsy in a clinical study is expected to reduce the
reported frequency of sSS. In fact, when biopsies were
not evaluated, the frequency of sSS ranged from 3.7%
to 24.3.27,28 In contrast, the frequency was shown to be
higher in this study (30.3%). Nevertheless, since it is an
invasive method, biopsy should be reserved for patients
who do not fulﬁll, or exclude, the criteria for the
diagnosis of SS.16 In this study, labial biopsy was
performed in 40 of 66 (60.6%) of the patients with
RA, and 11 of 40 (27.5%) showed a focus score
greater than 1 (4 mm2). Without the MSG biopsy, the
prevalence of sSS in this study would have dropped
from 30.3% to 19.69%, a level similar to that of other
studies.22,23,27 In the largest study of sSS, He et al.23
evaluated 509 RA patients but reported only 16 MSG
biopsies, which could have affected the SS prevalence
rate (14.5%).
Interestingly, the microscopic aspects of some MSG
specimens presented distinctive features not compatible
with SS diagnosis (intense salivary gland ﬁbrosis,
destruction of glandular parenchyma, and scarce
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there was a weak suggestion that the immunosuppres-
sive treatment might have changed the pattern of in-
ﬂammatory inﬁltration of the salivary gland,31 it was
not conﬁrmed by the one and only prospective study
that evaluated MSG biopsies at diagnosis and after SS
treatment.32 The authors could observe that the grade
and composition of inﬂammatory inﬁltration in MSG
remained unchanged throughout follow-up, suggesting
that the MSG inﬁltrates do not change signiﬁcantly
under immunosuppression. These ﬁndings support the
necessity of MSG biopsy even for patients under
immunosuppressive treatment, reinforcing it as a hall-
mark of SS diagnosis.
Barcelos et al.14 evaluated anti-CCP and RF levels in
Sjögren syndrome and observed a high RF positivity in
both RA and SS patients. Nevertheless, a high detection
of anti-CCP could be noted in RA but not in SS (6.9%),
ﬁndings similar to those of other studies, such as those
by Goëb et al.33 (4%), Gottenberg et al.34 (7.5%), and
Atzeni et al.35 (10%). It seems that anti-CCP can be
useful to distinguish between these diseases, and its
detection in pSS may be a predictor of future RA.14,35
Interestingly, in the present study, a higher prevalence
of anti-CCP was found in patients with RA/SS than in
those with RA, similar to the ﬁndings of Barcelos
et al.14 However, the present study demonstrated higher
levels of anti-CCP in RA patients than in patients with
RA/SS, but this was not statistically signiﬁcant (P ¼
.535). In this context, this marker did not appear to be
discriminatory of the secondary disease.36
RF is expected to be elevated in both RA and the two
clinical forms of SS.14 However, patients with RA/SS
seemed to have higher RF titers compared with
patients with pSS and joint disease.14 Nevertheless,
RF is also not a reliable diagnostic tool to
differentiate between pSS and RA, but it does seem
to have clinical implications in pSS, as it is associated
with inﬂammatory markers and pulmonary
involvement.14,37 Within the context of sSS, we
observed that RF was positive in a larger number of
patients with RA/SS in comparison with patients with
RA (75%  63%; P ¼ .149). Similarly, RF titers were
higher in patients with RA/SS than in those with RA
(221.06 UI/mL  128.99 UI/mL; P ¼ .235). However,
they were more frequent and more elevated in sSS
patients; thus, RF was also not helpful in differentiating
between these diseases.
We observed that patients with RA/SS were older
than patients with RA, as previously reported.23
However, markers of RA activity showed conﬂicting
results. The present study showed lower DAS28, that
is, lower activity of rheumatoid arthritis, in RA/SS,
whereas other authors reported the opposite.23 Disease
activity should point to early intervention andtreatment in order to avoid disease progression and
organ damage. It is still necessary to clarify whether
SS is associated with a higher level of disease
activity, in which case, this should lead to prompt
treatment. In addition, CRP and ESR did not differ
between RA and RA/SS. Since all patients (both RA
and RA/SS groups) were receiving ﬁrst-line treatment
exclusively with nonsteroidal anti-inﬂammatory, corti-
costeroid, and disease-modifying agents, this could
possibly have inﬂuenced the lack of difference.
CONCLUSIONS
In summary, this study showed that patients with RA/
SS present with a cluster of oral or ocular signs and
symptoms, and their presence should lead to a high
suspicion of SS among patients with RA. Furthermore,
it is important to perform MSG biopsy in order to
provide a proper diagnosis of sSS, even within the
context of immunosuppression. In addition, RF and
anti-CCP were not relevant for diagnosing sSS. Larger
prospective trials are necessary to adequately address
these observations.REFERENCES
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